Circ_0031242 Silencing Mitigates the Progression and Drug Resistance in DDP-Resistant Hepatoma Cells by the miR-924/POU3F2 Axis

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y31439937
   PubMed Web of Science ®Google Scholar
• Li S, Gao M, Li Z, et al. p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma. Front Biosci (Elite Ed). 2018;10:461–468.29772519
   PubMedGoogle Scholar
• Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–691. doi:10.1038/s41576-019-0158-731395983
   PubMed Web of Science ®Google Scholar
• Wu MY, Tang YP, Liu JJ, Liang R, Luo XL. Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells. J Cancer. 2020;11(10):2993–3001. doi:10.7150/jca.3985432226514
   PubMed Web of Science ®Google Scholar
• Li J, Qin X, Wu R, et al. Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis. J Cell Mol Med. 2020;24(9):5152–5161. doi:10.1111/jcmm.1516232222024
   PubMed Web of Science ®Google Scholar
• Luo Y, Fu Y, Huang R, et al. CircRNA_101505 sensitizes hepatocellular carcinoma cells to cisplatin by sponging miR-103 and promotes oxidored-nitro domain-containing protein 1 expression. Cell Death Discov. 2019;5(1):121. doi:10.1038/s41420-019-0202-631372241
   PubMed Web of Science ®Google Scholar
• Wang Y, Li Y, He H, Wang F. Circular RNA circ-PRMT5 facilitates non-small cell lung cancer proliferation through upregulating EZH2 via sponging miR-377/382/498. Gene. 2019;720:144099. doi:10.1016/j.gene.2019.14409931479715
   PubMed Web of Science ®Google Scholar
• Du W, Li D, Guo X, et al. Circ-PRMT5 promotes gastric cancer progression by sponging miR-145 and miR-1304 to upregulate MYC. Artif Cells Nanomed Biotechnol. 2019;47(1):4120–4130. doi:10.1080/21691401.2019.167185731701767
   PubMed Web of Science ®Google Scholar
• Ding Z, Guo L, Deng Z, Li P. Circ-PRMT5 enhances the proliferation, migration and glycolysis of hepatoma cells by targeting miR-188-5p/HK2 axis. Ann Hepatol. 2020;19(3):269–279. doi:10.1016/j.aohep.2020.01.00232089501
   PubMed Web of Science ®Google Scholar
• Ding B, Lou W, Xu L, Fan W. Non-coding RNA in drug resistance of hepatocellular carcinoma. Biosci Rep. 2018;38(5):BSR20180915. doi:10.1042/BSR2018091530224380
   PubMed Web of Science ®Google Scholar
• Espelt MV, Bacigalupo ML, Carabias P, Troncoso MF. MicroRNAs contribute to ATP-binding cassette transporter- and autophagy-mediated chemoresistance in hepatocellular carcinoma. World J Hepatol. 2019;11(4):344–358. doi:10.4254/wjh.v11.i4.34431114639
   PubMed Web of Science ®Google Scholar
• Fan H, Lv P, Mu T, et al. LncRNA n335586/miR-924/CKMT1A axis contributes to cell migration and invasion in hepatocellular carcinoma cells. Cancer Lett. 2018;429:89–99. doi:10.1016/j.canlet.2018.05.01029753758
   PubMed Web of Science ®Google Scholar
• Ding S, Jin Y, Hao Q, Kang Y, Ma R. LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connected with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis. Cancer Cell Int. 2020;20(1):6. doi:10.1186/s12935-019-1081-x31920461
   PubMed Web of Science ®Google Scholar
• Zhuo L, Liu J, Wang B, Gao M, Huang A. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep. 2013;29(2):555–562. doi:10.3892/or.2012.215523229111
   PubMed Web of Science ®Google Scholar
• Nugent M, Miller N, Kerin MJ. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol. 2012;106(8):947–952. doi:10.1002/jso.2317422648208
   PubMed Web of Science ®Google Scholar
• Präbst K, Engelhardt H, Ringgeler S, Hübner H. Basic colorimetric proliferation assays: MTT, WST, and resazurin. Methods Mol Biol. 2017;1601:1–17.28470513
   PubMedGoogle Scholar
• Stevens JJ, Graham B, Dugo E, et al. Arsenic trioxide induces apoptosis via specific signaling pathways in HT-29 colon cancer cells. J Cancer Sci Ther. 2017;9(1):298–306. doi:10.4172/1948-5956.100043228966729
   PubMedGoogle Scholar
• Kessler SM, Hosseini K, Hussein UK, et al. Hepatocellular carcinoma and nuclear paraspeckles: induction in chemoresistance and prediction for poor survival. Cell Physiol Biochem. 2019;52(4):787–801.30946555
   PubMedGoogle Scholar
• Qiu L, Xu H, Ji M, et al. Circular RNAs in hepatocellular carcinoma: biomarkers, functions and mechanisms. Life Sci. 2019;231:116660. doi:10.1016/j.lfs.2019.11666031319086
   PubMed Web of Science ®Google Scholar
• Zhou S, Wei J, Wang Y, Liu X. Cisplatin resistance-associated circRNA_101237 serves as a prognostic biomarker in hepatocellular carcinoma. Exp Ther Med. 2020;19(4):2733–2740. doi:10.3892/etm.2020.852632226487
   PubMed Web of Science ®Google Scholar
• Qi X, Zhang D-H, Wu N, et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52(10):710–718. doi:10.1136/jmedgenet-2015-10333426358722
   PubMed Web of Science ®Google Scholar
• Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–388. doi:10.1038/nature1199323446346
   PubMed Web of Science ®Google Scholar
• Miles DR, Shen J, Chuang AY, et al. Alpha-defensin 5 expression is regulated by microRNAs in the Caco-2 intestinal epithelial cell line. J Inflamm Bowel Dis Disord. 2016;1(1):105.27525335
   PubMedGoogle Scholar
• Lazzarini R, Caffarini M, Delli Carpini G, et al. From 2646 to 15: differentially regulated microRNAs between progenitors from normal myometrium and leiomyoma. Am J Obstet Gynecol. 2020;222(6):596.e1–596.e9. doi:10.1016/j.ajog.2019.12.016
   PubMed Web of Science ®Google Scholar
• Kobi D, Steunou AL, Dembélé D, et al. Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene. Pigment Cell Melanoma Res. 2010;23(3):404–418. doi:10.1111/j.1755-148X.2010.00697.x20337985
   PubMed Web of Science ®Google Scholar
• Chen H-Y, Islam A, Yuan T-M, et al. Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells. J Exp Clin Cancer Res. 2018;37(1):161. doi:10.1186/s13046-018-0837-930029680
   PubMed Web of Science ®Google Scholar
• Bishop JL, Thaper D, Vahid S, et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017;7(1):54–71. doi:10.1158/2159-8290.CD-15-126327784708
   PubMed Web of Science ®Google Scholar
• Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452–464. doi:10.1038/s41568-018-0005-829643473
   PubMed Web of Science ®Google Scholar
• Kumar A, Jaitak V. Natural products as multidrug resistance modulators in cancer. Eur J Med Chem. 2019;176:268–291. doi:10.1016/j.ejmech.2019.05.02731103904
   PubMed Web of Science ®Google Scholar
• Khalaf AM, Fuentes D, Morshid AI, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma. 2018;5:61–73. doi:10.2147/JHC.S15670129984212
   PubMed Web of Science ®Google Scholar
• Chen H, Liu S, Li M, Huang P, Li X. circ_0003418 inhibits tumorigenesis and cisplatin chemoresistance through Wnt/β-catenin pathway in hepatocellular carcinoma. Onco Targets Ther. 2019;12:9539–9549. doi:10.2147/OTT.S22950731807029
   PubMed Web of Science ®Google Scholar